These data suggest a key role for Notch 1 in mediating the resistance to regorafenib in colorectal cancer cells and may also provide a rationale to determine Notch 1 levels as a useful marker for the response to this treatment. This evidence concerns the gene NOTCH1 and colorectal cancer.